Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10391867 | 0.77 | KDM4E (0.32) | ALDH1A1RAB9AKDM4E | |
| SCHEMBL826789 | 0.77 | — | — | |
| SCHEMBL10391869 | 0.77 | KDM4E (0.32) | ALDH1A1RAB9AKDM4E | |
| SCHEMBL9342156 | 0.76 | — | — | |
| SCHEMBL826063 | 0.74 | CTSK (0.33) | ALDH1A1RAB9ACTSK | |
| SCHEMBL955332 | 0.71 | KMT2A (0.33) | ALDH1A1RAB9ACTSKKDM4E | |
| SCHEMBL2690540 | 0.70 | KMT2A (0.31) | ALDH1A1RAB9ACTSKKDM4E | |
| SCHEMBL8671705 | 0.70 | KMT2A (0.34) | ALDH1A1RAB9ACTSKKDM4E | |
| SCHEMBL10954993 | 0.69 | KMT2A (0.39) | ALDH1A1RAB9ACTSKKDM4E | |
| SCHEMBL4744556 | 0.69 | KMT2A (0.33) | ALDH1A1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174272-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-16 | — | — | US | disclosed |
| US-20210206781-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2021-07-08 | — | — | US | disclosed |
| US-10717748-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-07-21 | — | — | US | disclosed |
| US-20200157117-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2020-05-21 | — | — | US | disclosed |
| US-10550129-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-04 | — | — | US | disclosed |
| EP-2982666-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-08-07 | — | — | EP | disclosed |
| US-20190233436-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2019-08-01 | — | — | US | disclosed |
| US-10273245-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-04-30 | — | — | US | disclosed |
| US-20190071455-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2019-03-07 | — | — | US | disclosed |
| US-10174004-B2 | Production method of pyridazinone compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-01-08 | — | — | US | disclosed |
| EP-2123644-A1 | BENZOXAZEPINE DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-11-25 | — | — | EP | disclosed |
| WO-2009136663-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | WO | disclosed |
| US-20090270359-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| WO-2009119880-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-01 | — | — | WO | disclosed |
| US-20090163488-A1 | FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-25 | — | — | US | disclosed |
| US-20090137595-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-2049541-A2 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008150015-A1 | HETEROBICYCLIC COMPOUNDS AS KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008016192-A2 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157117-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PSEN1 | ALDH1A1 101/4885RAB9A 1428/4885CTSK 4102/4885 |
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | CBR3, CBR1, NOX5 | ALDH1A1 1105/4885RAB9A 3098/4885CTSK 3790/4885 |
| US-20190233436-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PSEN1 | ALDH1A1 101/4885RAB9A 1428/4885CTSK 4102/4885 |
| US-10273245-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | SNCA, HTT, PSEN1 | ALDH1A1 101/4885RAB9A 1428/4885CTSK 4102/4885 |
| US-20090137595-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | KDR, FLT1, FLT4 | ALDH1A1 182/4885RAB9A 855/4885CTSK 3673/4885 |
| US-11174272-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | SNCA, HTT, PSEN1 | ALDH1A1 101/4885RAB9A 1428/4885CTSK 4102/4885 |
| US-10717748-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | SNCA, HTT, PSEN1 | ALDH1A1 101/4885RAB9A 1428/4885CTSK 4102/4885 |
| US-10174004-B2 | Production method of pyridazinone compounds | PNPO, CYP2B6, CYP4B1 | ALDH1A1 966/4885RAB9A 2814/4885CTSK 3645/4885 |
| US-20090270359-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | AR, NR5A1, NR3C2 | ALDH1A1 816/4885RAB9A 4009/4885CTSK 4724/4885 |
| US-10550129-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | SNCA, HTT, PSEN1 | ALDH1A1 101/4885RAB9A 1428/4885CTSK 4102/4885 |
| US-20090163488-A1 | FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF | NOX3, NOX5, ZYX | ALDH1A1 2812/4885RAB9A 2528/4885CTSK 3493/4885 |
| US-20190071455-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PSEN1 | ALDH1A1 101/4885RAB9A 1428/4885CTSK 4102/4885 |
| US-20210206781-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PSEN1 | ALDH1A1 101/4885RAB9A 1428/4885CTSK 4102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.